Tiotropium Respimat Inhaler and the Risk of Death in COPD

Wise R. A., Anzueto A., Cotton D., Dahl R., Devins T., Disse B., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.369, sa.16, ss.1491-1501, 2013 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 369 Sayı: 16
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1056/nejmoa1303342
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1491-1501
  • Ankara Üniversitesi Adresli: Hayır

Özet

BackgroundTiotropium delivered at a dose of 5 g with the Respimat inhaler showed efficacy similar to that of 18 g of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.